Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Depreciation & Amortization (CF) (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Depreciation & Amortization (CF) for 4 consecutive years, with $128000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 33.68% to $128000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $633000.0, a 20.38% decrease, with the full-year FY2025 number at $633000.0, down 20.38% from a year prior.
  • Depreciation & Amortization (CF) was $128000.0 for Q4 2025 at Phathom Pharmaceuticals, down from $156000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $214000.0 in Q1 2024 to a low of $121000.0 in Q3 2023.
  • A 4-year average of $163937.5 and a median of $170000.0 in 2022 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 60.16% in 2024, then plummeted 33.68% in 2025.
  • Phathom Pharmaceuticals' Depreciation & Amortization (CF) stood at $168000.0 in 2022, then increased by 10.12% to $185000.0 in 2023, then rose by 4.32% to $193000.0 in 2024, then tumbled by 33.68% to $128000.0 in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Depreciation & Amortization (CF) are $128000.0 (Q4 2025), $156000.0 (Q3 2025), and $172000.0 (Q2 2025).